世界の肝炎検査市場は2021年の28億ドルから2026年までに36億ドルに達し、予測期間中のCAGRは4.7％と予想されます。世界の肝炎検査市場の成長を促す要因としては、肝炎の重い負担、輸血や献血の増加、POC機器とキットの利点、肝炎に関する意識向上の取組みなどが挙げられます。核酸検査の高額な費用、発展途上国での核酸検査の義務の欠如、好ましくない保険適応シナリオが肝炎市場の成長を抑制する可能性があります。新興市場、分子診断の技術的進歩、バイオテクノロジーとバイオ医薬品産業の成長は、市場のプレーヤーに強力な成長機会をもたらすことが期待されます。一方で、規制環境の変化、運用上の障壁、熟練した専門家の不足が、ある程度市場の成長を妨げる可能性があります。肝炎検査市場は、疾患の種類別、方式別、エンドユーザー別、地域別に分類されます。
COVID-19の発生は、病院への患者の通院数が減少したため、この市場に悪影響を及ぼしました。パンデミックは医療制度に大きな負担をかけています。医療機関や医療提供者は、疾患の蔓延を遅らせ、COVID-19患者の医療資源を節約するために、待機的手術と健康診断の実施を停止するように指示されました。その結果、多くの肝炎検査臨床検査室では検査量が急速に減少しました。
American Journal of Preventive Medicineによると、米国全体でC型肝炎の検査で有意な減少が見られました。論文「COVID-19パンデミック時のC型肝炎検査と治療の減少」によると、HCVの抗体検査が2020年4月に59％減少し、2020年7月に6％減少に戻ったことを示しています。HCV RNA検査が陽性の割合は2020年3月に62％、2020年7月に39％減少しました。
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 25)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
FIGURE 1 HEPATITIS TESTING MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 29)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1 GROWTH FORECAST
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.5.1 COVID-19-SPECIFIC ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
2.8 COVID-19 ECONOMIC ASSESSMENT
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
3 EXECUTIVE SUMMARY (Page No. - 42)
FIGURE 11 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 13 HEPATITIS TESTING MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 14 HEPATITIS TESTING MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 45)
4.1 HEPATITIS TESTING MARKET OVERVIEW
FIGURE 15 HIGH BURDEN OF HEPATITIS TO DRIVE MARKET GROWTH
4.2 HEPATITIS TESTING MARKET, BY TECHNOLOGY (2021-2026)
FIGURE 16 RAPID DIAGNOSTIC TESTS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
4.3 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE AND COUNTRY (2020)
FIGURE 17 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN HEPATITIS TESTING MARKET IN 2020
4.4 HEPATITIS TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 48)
5.1 INTRODUCTION
FIGURE 19 HEPATITIS TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 High burden of hepatitis
TABLE 1 HEPATITIS PREVALENCE, BY REGION, 2019 (MILLION)
5.2.1.2 Increasing blood transfusion and donations
TABLE 2 AVERAGE PREVALENCE OF HEPATITIS INFECTION IN BLOOD DONATIONS, BY INCOME GROUP
5.2.1.3 Benefits of POC instruments and kits
5.2.1.4 Awareness initiatives on hepatitis
5.2.2 RESTRAINTS
5.2.2.1 High cost of nucleic acid tests
5.2.2.2 Lack of mandates for nucleic acid tests in developing countries
5.2.2.3 Unfavorable reimbursement scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Rising technological advancements in molecular diagnostics
5.2.3.3 Growth in the biotechnology and biopharmaceutical industries
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape
5.2.4.2 Operational barriers
5.2.4.3 Shortage of skilled professionals
5.3 COVID-19 IMPACT ON THE HEPATITIS TESTING MARKET
6 HEPATITIS TESTING MARKET, BY DISEASE TYPE (Page No. - 55)
6.1 INTRODUCTION
TABLE 3 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 4 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
6.2 HEPATITIS B (HBV)
6.2.1 HEPATITIS B SEGMENT TO HOLD THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
TABLE 5 HEPATITIS B CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 2019
TABLE 6 HEPATITIS B TESTING MARKET, BY REGION, 2018-2020 (USD MILLION)
TABLE 7 HEPATITIS B TESTING MARKET, BY REGION, 2021-2026 (USD MILLION)
TABLE 8 NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 9 NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 10 EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 11 EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
6.3 HEPATITIS C (HCV)
6.3.1 GOVERNMENT INITIATIVES FOR SUPPORTING HCV DIAGNOSIS TO DRIVE MARKET GROWTH
TABLE 12 HEPATITIS C CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 2019
TABLE 13 HEPATITIS C TESTING MARKET, BY REGION, 2018-2020 (USD MILLION)
TABLE 14 HEPATITIS C TESTING MARKET, BY REGION, 2021-2026 (USD MILLION)
TABLE 15 NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 16 NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 17 EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 18 EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
6.4 OTHER HEPATITIS DISEASES
TABLE 19 REP0RTED HEPATITIS A CASES IN THE US SINCE 2016
TABLE 20 OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION, 2018-2020 (USD MILLION)
TABLE 21 OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION, 2021-2026 (USD MILLION)
TABLE 22 NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 23 NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 24 EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 25 EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
7 HEPATITIS TESTING MARKET, BY TECHNOLOGY (Page No. - 65)
7.1 INTRODUCTION
TABLE 26 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 27 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
7.2.1 ELISA IS WIDELY USED FOR THE DETECTION OF HEPATITIS
TABLE 28 HEPATITIS TESTING MARKET FOR ELISA, BY REGION, 2018-2020 (USD MILLION)
TABLE 29 HEPATITIS TESTING MARKET FOR ELISA, BY REGION, 2021-2026 (USD MILLION)
TABLE 30 NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 31 NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 32 EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 33 EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2021-2026 (USD MILLION)
7.3 RAPID DIAGNOSTIC TESTS (RDT)
7.3.1 RAPID TESTS ARE HIGHLY USEFUL IN COUNTRIES WITH LIMITED ACCESSIBILITY TO SOPHISTICATED TECHNOLOGIES
TABLE 34 HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2020 (USD MILLION)
TABLE 35 HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2021-2026 (USD MILLION)
TABLE 36 NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 37 NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 38 EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 39 EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2021-2026 (USD MILLION)
7.4 POLYMERASE CHAIN REACTION (PCR)
7.4.1 PCR TECHNOLOGY IS USED IN CONFIRMATORY TESTS FOR HEPATITIS DIAGNOSIS
TABLE 40 HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2018-2020 (USD MILLION)
TABLE 41 HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021-2026 (USD MILLION)
TABLE 42 NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 43 NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 44 EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 45 EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021-2026 (USD MILLION)
7.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
7.5.1 COST-BENEFITS OF INAAT ARE DRIVING THE GROWTH OF THIS MARKET SEGMENT
TABLE 46 HEPATITIS TESTING MARKET FOR INAAT, BY REGION, 2018-2020 (USD MILLION)
TABLE 47 HEPATITIS TESTING MARKET FOR INAAT, BY REGION, 2021-2026 (USD MILLION)
TABLE 48 NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 49 NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 50 EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 51 EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2021-2026 (USD MILLION)
7.6 OTHER TECHNOLOGIES
TABLE 52 HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018-2020 (USD MILLION)
TABLE 53 HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2026 (USD MILLION)
TABLE 54 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 55 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 56 EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 57 EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2026 (USD MILLION)
8 HEPATITIS TESTING MARKET, BY END USER (Page No. - 80)
8.1 INTRODUCTION
TABLE 58 HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 59 HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
8.2 HOSPITAL & DIAGNOSTIC LABORATORIES
8.2.1 HOSPITAL & DIAGNOSTIC LABORATORIES ARE THE LARGEST END USERS OF HEPATITIS TESTING PRODUCTS
TABLE 60 HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2020 (USD MILLION)
TABLE 61 HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2021-2026 (USD MILLION)
TABLE 62 NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 63 NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 64 EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 65 EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021-2026 (USD MILLION)
8.3 BLOOD BANKS
8.3.1 INCREASING NUMBER OF BLOOD DONATIONS TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
TABLE 66 HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION, 2018-2020 (USD MILLION)
TABLE 67 HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION, 2021-2026 (USD MILLION)
TABLE 68 NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 69 NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 70 EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 71 EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2026 (USD MILLION)
8.4 OTHER END USERS
TABLE 72 HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION, 2018-2020 (USD MILLION)
TABLE 73 HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION, 2021-2026 (USD MILLION)
TABLE 74 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 75 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 76 EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 77 EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2026 (USD MILLION)
9 EPATITIS TESTING MARKET, BY REGION (Page No. - 89)
9.1 INTRODUCTION
TABLE 78 GLOBAL: HEPATITIS TESTING MARKET, BY REGION, 2018-2020 (USD MILLION)
TABLE 79 GLOBAL: HEPATITIS TESTING MARKET, BY REGION, 2021-2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 20 NORTH AMERICA: HEPATITIS TESTING MARKET SNAPSHOT
TABLE 80 NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 81 NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 82 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 83 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 84 NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 85 NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 86 NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 87 NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
9.2.1 US
9.2.1.1 High healthcare expenditure to drive market growth in the US
TABLE 88 US: NUMBER OF HEPATITIS A CASES REPORTED, 2015 VS. 2019
TABLE 89 HEPATITIS A PREVALENCE RATE PER 100,000 POPULATION IN THE US, 2013-2017
TABLE 90 US: KEY MACROINDICATORS
TABLE 91 US: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 92 US: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 93 US: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 94 US: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 95 US: HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 96 US: HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Favorable government initiatives are expected to boost market growth in Canada
TABLE 97 CANADA: KEY MACROINDICATORS
TABLE 98 CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 99 CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 100 CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 101 CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 102 CANADA: HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 103 CANADA: HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
9.3 EUROPE
TABLE 104 NUMBER OF HEPATITIS B CASES IN EUROPE, BY COUNTRY, 2014-2018
TABLE 105 EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 106 EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 107 EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 108 EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 109 EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 110 EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 111 EUROPE: HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 112 EUROPE: HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Increasing demand for advanced diagnostic technologies to drive market growth in Germany
TABLE 113 GERMANY: KEY MACROINDICATORS
TABLE 114 GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 115 GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 116 GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 117 GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 118 GERMANY: HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 119 GERMANY: HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
9.3.2 UK
9.3.2.1 Increasing number of clinical laboratories to drive market growth in the UK
TABLE 120 NUMBER OF HEPATITIS C CASES REPORTED IN ENGLAND AND WALES, 2008-2018
TABLE 121 UK: KEY MACROINDICATORS
TABLE 122 UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 123 UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 124 UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 125 UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 126 UK: HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 127 UK: HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
9.3.3 REST OF EUROPE
TABLE 128 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP)
TABLE 129 ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 130 ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 131 ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 132 ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 133 ROE: HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 134 ROE: HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
9.4 ASIA PACIFIC
9.4.1 HIGH PREVALENCE OF HEPATITIS TO BOOST MARKET GROWTH
TABLE 135 ASIA PACIFIC: ESTIMATED PREVALENCE OF CHRONIC HBV AND HCV
TABLE 136 ASIA PACIFIC: COST COVERAGE FOR THE DIAGNOSIS OF CHRONIC VIRAL HEPATITIS
FIGURE 21 ASIA PACIFIC: HEPATITIS TESTING MARKET SNAPSHOT
TABLE 137 CHINA: KEY MACROINDICATORS
TABLE 138 JAPAN: KEY MACROINDICATORS
TABLE 139 INDIA: KEY MACROINDICATORS
TABLE 140 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 141 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 142 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 143 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 144 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 145 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
9.5 REST OF THE WORLD
9.5.1 LESS-STRINGENT REGULATIONS FOR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH
TABLE 146 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 147 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 148 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 149 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 150 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 151 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER, 2021-2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 123)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 152 OVERVIEW OF STRATEGIES ADOPTED BY KEY HEPATITIS TESTING MARKET PLAYERS
10.3 MARKET SHARE ANALYSIS
FIGURE 22 HEPATITIS TESTING MARKET SHARE ANALYSIS, 2020
TABLE 153 HEPATITIS TESTING MARKET: DEGREE OF COMPETITION (2020)
10.4 COMPANY EVALUATION QUADRANT
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE PLAYERS
10.4.4 PARTICIPANTS
FIGURE 23 HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT (2020)
10.5 COMPANY EVALUATION QUADRANT: SMES/START-UPS
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 RESPONSIVE COMPANIES
10.5.4 DYNAMIC COMPANIES
FIGURE 24 HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT FOR SMES & START-UPS (2020)
10.6 COMPETITIVE SCENARIO
10.6.1 PRODUCT LAUNCHES & APPROVALS
TABLE 154 PRODUCT LAUNCHES & APPROVALS
10.6.2 DEALS
TABLE 155 DEALS
10.6.3 OTHER DEVELOPMENTS
TABLE 156 OTHER DEVELOPMENTS
10.7 COMPANY FOOTPRINT ANALYSIS
TABLE 157 TECHNOLOGY, DISEASE TYPE, AND REGIONAL FOOTPRINT OF COMPANIES
TABLE 158 TECHNOLOGY FOOTPRINT OF COMPANIES
TABLE 159 DISEASE TYPE FOOTPRINT OF COMPANIES
TABLE 160 REGIONAL FOOTPRINT OF COMPANIES
11 COMPANY PROFILE (Page No. - 135)
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats)*
11.1.1 ABBOTT LABORATORIES
TABLE 161 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
11.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 162 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 26 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
11.1.3 BIO-RAD LABORATORIES, INC.
TABLE 163 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 27 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
11.1.4 SIEMENS HEALTHINEERS AG
TABLE 164 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 28 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2020)
11.1.5 DIASORIN S.P.A
TABLE 165 DIASORIN S.P.A: BUSINESS OVERVIEW
FIGURE 29 DIASORIN S.P.A.: COMPANY SNAPSHOT (2020)
11.1.6 QIAGEN
TABLE 166 QIAGEN: BUSINESS OVERVIEW
FIGURE 30 QIAGEN: COMPANY SNAPSHOT (2020)
11.1.7 DANAHER CORPORATION
TABLE 167 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
11.1.8 GRIFOLS, S.A.
TABLE 168 GRIFOLS, S.A.: BUSINESS OVERVIEW
FIGURE 32 GRIFOLS, S.A.: COMPANY SNAPSHOT (2020)
11.1.9 BIOMÉRIEUX SA
TABLE 169 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 33 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
11.1.10 ORTHO CLINICAL DIAGNOSTICS
TABLE 170 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 34 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020)
11.2 OTHER PLAYERS
11.2.1 FUJIREBIO US, INC.
11.2.2 ORASURE TECHNOLOGIES
11.2.3 EPITOPE DIAGNOSTICS
11.2.4 TRIVITRON HEALTHCARE
11.2.5 MERIL LIFE SCIENCES PVT. LTD.
11.2.6 GENMARK DIAGNOSTICS INC.
11.2.7 VELA DIAGNOSTICS
11.2.8 MOLBIO DIAGNOSTICS PVT. LTD.
11.2.9 GENEOMBIO TECHNOLOGIES PVT. LTD.
11.2.10 MEDMIRA INC.
*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 174)
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
